Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott grows in emerging markets

This article was originally published in The Tan Sheet

Executive Summary

Abbott's worldwide nutrition sales jump 11.8 percent to $1.32 billion in the first quarter, benefiting from foreign exchange and continued growth in emerging markets. International nutritional sales climbed 18.1 percent to $678 million in the January-March period, while the U.S. grew 5.9 percent to $642 million, the Abbott Park, Ill., firm reported April 21. Sales of adult nutrition brands, including Ensure and Glucerna, climbed 10.3 percent in the U.S. and 20.6 percent internationally. VP of Investor Relations John Thomas said in an earnings call. Abbott Nutrition in China is growing twice the market rate. While Abbott's deal to buy Wockhardt's Indian nutritional business was called off, Abbott likely seeks other nutritional opportunities in India (1"The Tan Sheet" April 5, 2010). In the quarter, the company recorded total sales of $7.7 billion, a 14.6 percent gain over the year-ago quarter

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel